Apotex Plavix Saga May Finally Be Over; Judge Asks “What Is Going On In This Case?”
This article was originally published in The Pink Sheet Daily
Executive Summary
Apotex sought $3.4 billion in damages, claiming Bristol-Myers Squibb scuttled their patent settlement agreement by submitting a false certification to the FTC that it had no oral commitment not to sell an authorized generic of Plavix during Apotex’s exclusivity period; Apotex had told the FTC there was such a side deal.